Loading clinical trials...
Loading clinical trials...
A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age
Conditions
Interventions
rBCG-N-hRSV 1/100
rBCG-N-hRSV 1/10
+2 more
Locations
1
Chile
Pontificia Universidad Católica de Chile
Santiago, Chile
Start Date
June 27, 2017
Primary Completion Date
June 1, 2018
Completion Date
June 1, 2018
Last Updated
December 11, 2020
NCT07220109
NCT07092865
NCT07239583
NCT06534892
NCT04919109
NCT07235397
Lead Sponsor
Pontificia Universidad Catolica de Chile
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions